Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo
Stephanie M. Cohen, Ridhwi Mukerji, Shuang Cai, Ivan Damjanov, M. Laird Forrest, Mark S. Cohen
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo'. Together they form a unique fingerprint.